Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in ...

The current $195 million investment is part of a commitment to invest more than $10 billion for innovation and manufacturing capacity enhancement.

AbbVie is investing $195m to strengthen domestic active pharmaceutical ingredient (API) production within the US, with the ...

H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The ...

Genmab (Otc) (($GMAB)) has held its Q2 earnings call. Read on for the main highlights of the call. Genmab’s recent earnings call reflects a ...

There is competition out there though, notably from Abbvie/Genmab's CD20xCD3 bispecific epcoritamab, which impressed in the EPCORE NHL-1 trial in third-line or later large B-cell lymphoma and will ...